Biogened (WAR:BGD) GF Value Rank: 10 (As of Sep. 07, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
75 GF Score
Price zł19.90
GF Value zł24.32
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened GF Value Rank?

Biogened WAR:BGD +4.74% 75 GF Value Rank is 10 as of Sep. 07, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates WAR:BGD with a GF Score™ of 75/100 and a GF Value™ of zł24.32 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biogened has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


WAR:BGD vs ZTS, UTHR, VTRS: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogened GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogened's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Biogened's GF Value Rank falls into.


WAR:BGD
75GF Score
Biogened SA WAR:BGD
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Biogened (WAR:BGD) has a GF Value Rank of 10 as of Sep. 07, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Biogened and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, Biogened's GF Value Rank has ranged from 1.00 to 10.00.
Is Biogened's GF Value Rank too high?
Biogened's current GF Value Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Biogened has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's GF Value Rank compare to ZTS and UTHR?
Biogened's GF Value Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Biogened's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Biogened and its competitors. Biogened's current GF Value Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.32, compared to a current price of zł19.90 — trading 18.2% below its estimated fair value. The current GF Value Rank is 10, which is 67% above median its 10-year median of 6.00. Biogened's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Biogened (WAR:BGD), the current GF Value Rank is 10 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł19.90 is trading 18.2% below its estimated GF Value™ of zł24.32. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • GF Value Rank: 10 (67% above median its 10-year median of 6.00)
  • GF Value™: zł24.32 vs. price of zł19.90 (18.2% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
75GF Score

Get the complete analysis for WAR:BGD

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.90
Price
zł24.32
GF Value